ILMN vs PACB
ILMN: Illumina is the global leader in DNA sequencing and array technologies that are foundational to modern genomics research and clinical diagnostics. PACB: Pacific Biosciences provides high-accuracy, long-read genomic sequencing solutions that enable researchers and clinicians to solve complex genetic challenges.
Side-by-side fundamentals
| Metric | ILMN | PACB | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $190.87 | $1.38 | |
| Market cap as of 2026-07-23 | $29.2B | $435M | |
| P/E as of 2026-07-23 | 34.24 | n/a | |
| PEG as of 2026-07-23 | 2.91 | n/a | |
| Net margin as of 2026-07-23 | +19.4% | -80.3% | ILMN higher |
| Gross margin as of 2026-07-23 | +66.7% | +40.3% | ILMN higher |
| Operating margin as of 2026-07-23 | +19.3% | -83.3% | ILMN higher |
| ROE as of 2026-07-23 | +34.0% | -488.4% | ILMN higher |
| ROA as of 2026-07-23 | +13.4% | -16.1% | ILMN higher |
| Debt / equity as of 2026-07-23 | 0.74 | 272.23 | ILMN lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.3% | +5.0% | PACB higher |
| Revenue CAGR (3y) SEC XBRL | -1.4% | -6.9% | ILMN higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 1.47 | 2.35 | |
| 1-year return as of 2026-07-22 close | +87.1% | -14.8% | ILMN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.